ClinicalTrials.gg
RecruitingNCT06429982Updated Jul 3, 2025

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

A Phase 1 interventional study of Dexamethasone and Placebo in Rhabdomyolysis, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Open to participants aged 6 Months to 25 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Children's National Research Institute · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.
Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
6 Months to 25 Years
Sex
All
01

Study summary

There is a significant unmet need for optimized treatment in rhabdomyolysis. There are few prospective interventional studies on treatment for rhabdomyolysis, a condition which affects diverse and underrepresented populations at a higher rate. While steroids are often used off-label, a systematic study has not yet been initiated, and steroids have not been yet considered in as a consideration to standard care guidelines.

The hypothesis is that patients who receive dexamethasone in addition to standard care versus placebo and standard care will have improvement in pain, length of hospital stay, and decrease in kidney complications.

Read the detailed description

Study Objective:

This is a single center, 2-year, blinded prospective randomized study for those diagnosed with rhabdomyolysis age six months-25 years using dexamethasone versus placebo treatment in addition to standard care in up to 50 patients.

Study Design:

Patients will be enrolled with a 2:1 ratio of treatment of dexamethasone for 5 days versus placebo treatment for 5 days in addition to receiving standard care. The treatment period for each subject will be five days treatment with oral treatment once per day with study drug (dexamethasone versus placebo). All patients will also receive standard care. Patients and their parent/ caregiver will have the option to complete surveys before and after treatment in order to assess pain level and treatment improvement. Chart review will be performed on all patients throughout and after the five-day study treatment period. There will be no additional interventions.

02

Conditions studied

  • Rhabdomyolysis

Browse trials for

03

In context

Rhabdomyolysis

40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 14 interventional studies indexed under Rhabdomyolysis.

Browse Rhabdomyolysis studies →

Lead sponsor

Children's National Research Institute is the lead sponsor of 127 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of rhabdomyolysis defined as creatine kinase> 5000 with trauma excluded
  2. Ability of parents/patients to understand and the willingness to sign a written document.
  3. Patients ages 12 and older will sign written assent

Exclusion criteria

Exclusion Criteria:

  • Already taking systemic .
  • Inability to comply with study instructions.
  • Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women.

    o A urine pregnancy test will be performed for women of .

  • Below gestational age of 40 weeks
  • Allergy to fluconazole, clotrimazole or nystatin.
  • Cannot tolerate PO medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Dexamethasone group

    Dexamethasone five days with 0.6 mg/ kg dose per day max 16 mg dose. Standard care will also be provided.

    Drug: Dexamethasone

  • Placebo comparator
    Placebo group

    Placebo for five days with one dose per day placebo oral dosing. Standard care will also be provided.

    Drug: Placebo

Interventions

  • Steroid five day treatment

    Also known as: DexPak

  • DrugPlacebo

    Placebo control group

    Also known as: Sugar Pill

06

What researchers measure

Primary outcomes

  1. Length of Stay

    Number of days Length of Stay in Each Group

    Time frame: Primarily 5 days - 1 year

  2. Muscle breakdown

    Creatinine Kinase trend comparison between groups

    Time frame: Primarily 5 days - 1 year

  3. Renal complications

    Bun/ Creatinine

    Time frame: Primarily 5 days - 1 year

Secondary outcomes

  1. Quantitative Pain Outcomes

    EHR pain scores

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016 Jun 15;20(1):135. doi: 10.1186/s13054-016-1314-5. PubMed 27301374 ↗
  • Summerlin ML, Regier DS, Fraser JL, Chapman KA, Kafashzadeh D, Billington C Jr, Kisling M, Grochowsky A, Ah Mew N, Shur N. Use of dexamethasone in idiopathic, acute pediatric rhabdomyolysis. Am J Med Genet A. 2021 Feb;185(2):500-507. doi: 10.1002/ajmg.a.62000. Epub 2020 Dec 10. PubMed 33300687 ↗
  • Szugye HS. Pediatric Rhabdomyolysis. Pediatr Rev. 2020 Jun;41(6):265-275. doi: 10.1542/pir.2018-0300. PubMed 32482689 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
May 28, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 31, 2026
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06429982
Responsible party
Natasha Shur (MD, Principal Investigator, Professor, Children's National Research Institute) — Principal investigator
First posted
May 28, 2024
Start date
Oct 1, 2024
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 3, 2025

Study contacts

Natasha Shur, MD
Contact
nshur2@childrensnational.org
202-476-5000
Natasha Shur, MD
Contact
nshur2@childrensnational.org
Natasha Shur, MD
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion